EFMC-ASMC’19 “EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry”. Athens, Greece September 1-5, 2019

We have also the pleasure to present a the following scientific communication:

“BIOPHYSICS AND STRUCTURAL BIOLOGY FOR THE SOSA APPROACH: DEVELOPMENT OF HASPIN INHIBITORS VIA THE OPTIMIZATION OF THE SIDE ACTIVITY OF PIM1 INHIBITORS”.

Gilbert BEY (1), Pierre-Emmanuel BROUTIN (1), Pascal MULLER (1), Paola CIAPETTI (1), Nathalie WEIDNER (1), Dominique Roecklin (1), Thomas NEUMANN (1), Jan EHLERT (2), Michael KUBBUTAT (2)

1) NovAliX, 850 bd Sébastien Brant F‐67400 Illkirch, France

2) ProQinase, Breisacher Str. 117 D‐79106 Freiburg, Germany

With the aim of testing our drug discovery tool-box to identify therapeutic relevant compounds, PIM1 was selected as target of choice. PIM1 is a serine/threonine kinase involved in leukemia, lymphoma and prostate cancer, but also in pulmonary hypertension. PIM1 has a recognized role in T cell development and has been implicated in the pathogenesis of autoimmunity.

POSTER nº173